Intensive therapy not superior for diabetes complications

May 20, 2014
Intensive therapy not superior for diabetes complications

(HealthDay)—Compared with routine care, early multifactorial therapy did not result in superior microvascular outcomes at five years in individuals with screening-detected diabetes, according to research published online May 1 in Diabetes Care.

Annelli Sandbaek, M.D., Ph.D., of the University of Aarhus in Denmark, and colleagues followed up 2,861 of 3,057 individuals with type 2 diabetes detected by screening who had been randomly assigned to intensive treatment or routine care. The authors sought to assess the effect of treatment type on .

The researchers found, at five years, in the intensive treatment group and the routine care group, respectively, any kind of albuminuria in 22.7 and 24.4 percent of individuals (odds ratio [OR], 0.87; 95 percent confidence interval [CI], 0.72 to 1.07), retinopathy in 10.2 and 12.1 percent (OR, 0.84; 95 percent CI, 0.64 to 1.10), and neuropathy in 4.9 and 5.9 percent (OR, 0.95; 95 percent CI, 0.68 to 1.34). Between baseline and follow-up, estimated increased in both groups (4.31 and 6.44 mL/min, respectively).

"Compared with routine care, an intervention to promote target-driven, intensive management of patients with detected by screening was not associated with significant reductions in the frequency of microvascular events at five years," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including those which contributed funding to the study.

Explore further: Metformin use doesn't cut incidence of bladder cancer

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Metformin use doesn't cut incidence of bladder cancer

February 11, 2014

(HealthDay)—For patients with type 2 diabetes, metformin use is not associated with a significantly reduced risk of bladder cancer, according to a study published online Feb. 4 in Diabetes Care.

Interarm BP difference may up cardiac risk in diabetes

April 3, 2014

(HealthDay)—Interarm differences in systolic blood pressure (BP) in patients with diabetes may be associated with an increased risk of cardiovascular morbidity and mortality, according to research published online on March ...

Serum marker predicts cardiovascular events in diabetes

April 25, 2014

(HealthDay)—Elevated levels of polyclonal serum immunoglobulin combined free light chains (cFLCs) may indicate adverse cardiovascular disease (CVD) outcomes in patients with type 2 diabetes, according to research published ...

Many at high cardiovascular risk still not on statins

May 13, 2014

(HealthDay)—Many individuals at high risk for cardiovascular events, such as those with coronary artery disease, diabetes, or both, are not receiving statins, according to research published in the May/June issue of the ...

Recommended for you

Engineered hot fat implants reduce weight gain in mice

August 20, 2015

Scientists at the University of California, Berkeley, have developed a novel way to engineer the growth and expansion of energy-burning "good" fat, and then found that this fat helped reduce weight gain and lower blood glucose ...

Promising progress for new treatment of type 1 diabetes

July 30, 2015

New research from Uppsala University shows promising progress in the use of anti-inflammatory cytokine for treatment of type 1 diabetes. The study, published in the open access journal Scientific Reports, reveals that administration ...

Bacteria may cause type 2 diabetes

June 1, 2015

Bacteria and viruses have an obvious role in causing infectious diseases, but microbes have also been identified as the surprising cause of other illnesses, including cervical cancer (Human papilloma virus) and stomach ulcers ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.